Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
复制标题
中期和治疗后 F-18-FDG PET/CT 扫描对成年伯基特淋巴瘤患者的预后价值
DOI：
10.1186/s40880-015-0057-z
复制
发表时间：
2015-12-02
影响因子：
--
通讯作者：
Li ZM
中科院分区：
文献类型：
--
作者：
Wei WX;Huang JJ;Li WY;Zhang X;Xia Y;Jiang WQ;Fan W;Li ZM
在几种淋巴瘤的几种亚类中，已经证实了临床和疗法后氟-18-氟脱氧葡萄糖（18F-FDG）极性发射断层扫描（PET）和PET/COMPEL层析成像（CT）扫描的预后值。在伯基特的淋巴瘤中，本研究的目的尚未明确定义。淋巴瘤。
共有29名新诊断为伯基特淋巴瘤的成年患者参与了这项研究，其中23名患者接受了基线PET/CT，15例患者接受了1-4次化学疗法后的治疗宠物/CT所有计划的一线化学疗法周期后，治疗后的PET/CT。根据国际统一项目的标准，视觉上的摄取值（∆Suvmax）的标准为25％，50％和75％。自由生存（PFS）被认为是主要终点。
中值OS和PFS为27.6个月（6.5-78.3个月）和27.2个月（范围为3.0–78.3个月），基线PET/CT的中位数为18.3（范围1.6-35.9）在治疗和治疗后PET/CT分别为4.0（范围0-17.6）和3.0（范围0-14.5）。 （ECOG）得分（<2vs.≥2）与基线PET/CT SUVMAX显着相关。从基线到治疗后PET/CT的最佳临界ΔSuvmax可以预测Burkitt淋巴瘤患者OS的变化为50％（P = 0.019）。
18F-FDG的摄取在Burkitt的淋巴瘤中是强烈的，在临时和治疗后PET/CT程序中，Suvmax显着降低了。患者。
The prognostic values of interim and post-therapy fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) scanning have been confirmed in several subtypes of lymphoma. However, its prognostic value in Burkitt’s lymphoma has not been clearly defined. The aim of the present study was to assess the prognostic value of PET/CT scanning during different treatment processes of Burkitt’s lymphoma. A total of 29 adult patients with newly diagnosed Burkitt’s lymphoma were retrospectively involved in this study; of them, 23 patients underwent baseline PET/CT, 15 patients underwent mid-therapy PET/CT after 1–4 cycles of chemotherapy, and 17 patients underwent post-therapy PET/CT after all planned first-line chemotherapy cycles. Mid-therapy and post-therapy PET/CT results (positive vs. negative) were visually interpreted according to the criteria of the International Harmonization Project. The reduction in the maximum standardizes uptake values (∆SUVmax) of 25%, 50%, and 75% were regarded as cutoff points. Overall survival (OS) and progression-free survival (PFS) were regarded as the major endpoints. The median OS and PFS were 27.6 months (range 6.5–78.3 months) and 27.2 months (range 3.0–78.3 months), respectively. The median SUVmax of the baseline PET/CT was 18.3 (range 1.6–35.9), whereas the median SUVmax of the mid-therapy and post-therapy PET/CT decreased to 4.0 (range 0–17.6) and 3.0 (range 0–14.5), respectively. The patients’ Eastern Cooperative Oncology Group (ECOG) scores (<2 vs. ≥2) were significantly associated with the baseline PET/CT SUVmax. The mid-therapy and post-therapy PET/CT results (positive vs. negative) showed no significant association with OS or PFS. The optimal cutoff ∆SUVmax from the baseline to the post-therapy PET/CT that could predict a change in OS in patients with Burkitt’s lymphoma was 50% (P = 0.019). 18F-FDG uptake was intense in Burkitt’s lymphoma, and there was a significant reduction in SUVmax during the interim and post-therapy PET/CT procedures. A ∆SUVmax of greater than 50% was a favorable cutoff point to predict the OS of Burkitt’s lymphoma patients.